FDA’s Office Of Chief Counsel Rejects 3%-5% Of Warning Letters – Troy
This article was originally published in The Pink Sheet Daily
Executive Summary
The OCC’s clearance process is five days for warning letters, 15 days for untitled letters, FDA’s outgoing top lawyer says. Despite initial skepticism, Troy sees “emerging consensus” that OCC review has added value.
You may also be interested in...
FDA Acting Chief Counsel To Be Masoudi
Dan Troy will leave agency Nov. 24 after three years which included major Waxman/Hatch reforms and reconsideration of First Amendment issues. Newly appointed deputy chief counsel Masoudi will succeed Troy until a permanent chief counsel is selected by HHS’ Azar.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.